Generic drug: meloxicam

Brand name: Vivlodex

What is Vivlodex (meloxicam), and how does it work?

Vivlodex (meloxicam) is a non-steroidal anti-inflammatory drug indicated for management of osteoarthritis (OA) pain.

What are the side effects of Vivlodex?

WARNING

RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
  • Vivlodex is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Bleeding, Ulceration, and Perforation

  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

Common side effects of Vivlodex include:

What is the dosage for Vivlodex?

  • Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.
  • For management of osteoarthritis pain, the recommended starting dosage is 5 mg orally once daily. Dose may be increased to 10 mg in patients who require additional analgesia. The maximum recommended daily oral dose of Vivlodex is 10 mg.
  • In patients on hemodialysis, the maximum daily dosage is 5 mg

Non-Interchangeability With Other Formulations Of Meloxicam

  • Vivlodex capsules have not shown equivalent systemic exposure to other formulations of oral meloxicam. Therefore, Vivlodex capsules are not interchangeable with other formulations of oral meloxicam even if the total milligram strength is the same.
  • Do not substitute similar dose strengths of other meloxicam products.

What drugs interact with Vivlodex?

See Table 3 for clinically significant drug interactions with meloxicam.

Table 3 : Clinically Significant Drug Interactions with meloxicam

Drugs That Interfere with Hemostasis
Clinical Impact:
  • Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.
  • Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.
Intervention: Monitor patients with concomitant use of Vivlodex with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding.
Aspirin
Clinical Impact: Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone.
Intervention: Concomitant use of Vivlodex and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding.
ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers
Clinical Impact:
  • NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).
  • In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.
Intervention:
  • During concomitant use of Vivlodex and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.
  • During concomitant use of Vivlodex and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function.
Diuretics
Clinical Impact: Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.
Intervention: During concomitant use of Vivlodex with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects
Digoxin
Clinical Impact: The concomitant use of meloxicam with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
Intervention: During concomitant use of Vivlodex and digoxin, monitor serum digoxin levels.
Lithium
Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium
clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.
Intervention: During concomitant use of Vivlodex and lithium, monitor patients for signs of lithium toxicity.
Methotrexate
Clinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).
Intervention: During concomitant use of Vivlodex and methotrexate, monitor patients for methotrexate toxicity.
Cyclosporine
Clinical Impact: Concomitant use of Vivlodex and cyclosporine may increase cyclosporine’s nephrotoxicity.
Intervention: During concomitant use of Vivlodex and cyclosporine, monitor patients for signs of worsening renal function.
NSAIDs and Salicylates
Clinical Impact: Concomitant use of meloxicam with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy.
Intervention: The concomitant use of meloxicam with other NSAIDs or salicylates is not recommended.
Pemetrexed
Clinical Impact: Concomitant use of Vivlodex and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).
Intervention: During concomitant use of Vivlodex and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.

QUESTION

What joints are most often affected by osteoarthritis? See Answer

Is Vivlodex safe to use while pregnant or breastfeeding?

  • Use of NSAIDs, including Vivlodex, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus.
  • Avoid use of NSAIDs, including Vivlodex, in pregnant women starting at 30 weeks of gestation (third trimester).
  •  There are no adequate and well-controlled studies of Vivlodex in pregnant women.
  • Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive.
  • There are no human data available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production.
  • The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Vivlodex and any potential adverse effects on the breastfed infant from the Vivlodex or from the underlying maternal condition.

Summary

Vivlodex (meloxicam) is a non-steroidal anti-inflammatory drug indicated for management of osteoarthritis (OA) pain. Serious side effects of Vivlodex include increased risk of serious cardiovascular thrombotic events (heart attack and stroke, which can be fatal) and increased risk of serious gastrointestinal (GI) adverse events (bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal).

Treatment & Diagnosis

Medications & Supplements

SLIDESHOW

Exercises for Knee Osteoarthritis and Joint Pain See Slideshow

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 5/7/2021
References
All sections courtesy of the U.S. Food and Drug Administration